Cardiothoracic & vascular anesthesia
Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: A randomized controlled trial
Authors' conclusion
In this randomized controlled trial, administration of FCM on postoperative day 1 in non-anemic patients undergoing cardiac surgery increased hemoglobin levels by 0.8 g/dL on postoperative day 30, leading to reduced transfusion rate, and improved iron levels on postoperative day 5 and 30.
Study context
- Population
- Non-anemic patients undergoing cardiac surgery
- Participants
- 195 patients
- Comparison
- Ferric carboxymaltose 1 g intravenous (IV) vs placebo on POD 1
- Ferric carboxymaltose (FCM)n = 97
- Placebon = 98reference
- Primary endpoint
- Hemoglobin level
- Follow-up
- Day 30
Methodological detailssingle-center, double-blind, placebo-controlled, parallel-group
- Single-center
- Double-blind
- Placebo-controlled
- Parallel-group
Primary result
As reported in the abstract
95% CI 0.41–1.23; P < 0.001
Secondary outcomes
| Outcome | FCM | Placebo | P value |
|---|---|---|---|
| Transfused blood units | median 1 (IQR 0–2) unit | median 2 (IQR 0–3) units | P = 0.037 |
Iron balance
- Significant improvement in iron balance with FCM vs control
Safety
- No side effects associated with FCM administration reported
Original publication
Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: A randomized controlled trial. Anaesth Crit Care Pain Med. Published 11 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →